v3.25.1
Segment Information (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2025
USD ($)
segment
Mar. 31, 2024
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 1  
Segment Reporting, Asset Reconciling Item [Line Items]    
License and other revenue $ 15,000 $ 0
Other R&D expenses:    
General and administrative expenses (12,334) (13,438)
Share-based compensation 7,883 8,154
Interest income 7,890 2,591
Interest expense (2,877) (2,529)
Income tax expense 1,397 481
Consolidated net loss (26,135) (38,046)
Reportable Segment    
Segment Reporting, Asset Reconciling Item [Line Items]    
License and other revenue 15,000 0
Less:    
OX2R agonist program expenses (20,093) (4,652)
LockBody program expenses (3,418) (4,170)
Discontinued R&D program expenses (2,917) (11,942)
Other R&D expenses:    
Personnel expenses (6,302) (5,599)
Research tax incentives 4,259 7,860
Other preclinical and clinical development expenses (815) (424)
General and administrative expenses (8,608) (9,009)
Share-based compensation (7,883) (8,154)
Interest income 7,890 2,591
Interest expense (2,877) (2,529)
Other segment items 1,026 (1,537)
Income tax expense (1,397) (481)
Consolidated net loss $ (26,135) $ (38,046)